Agoracom Blog Home

Posts Tagged ‘CSE’

CLIENT FEATURE: Tartisan Nickel $TN.ca Kenbridge Property Hosts M&I Resource of 7.14 Million Tonnes of 0.62% Nickel + 0.33% Copper – $ROX.ca $FF.ca $EDG.ca $AGL.ca $ANZ.ca

Posted by AGORACOM-JC at 2:05 PM on Tuesday, April 21st, 2020
Tc logo in black

Investment Highlights

  • Kenbridge property has a measured and indicated resource of 7.14 million tonnes at 0.62% nickel, 0.33% copper
  • 17.5 (21.8 fully diluted) percent equity stake in Eloro Resources and 2 percent NSR in their La Victoria property

Kenbridge Ni Project (ON, Canada)

  • Advanced  stage  deposit  remains open  in  three  directions,  is  equipped with a 623m  deep  shaft  and  has  never  been  mined
  • Preliminary  Economic Assessment completed and updated returned robust project 
    economics and operating costs including  a  NPV  of  C$253M  and  cash costs of US$3.47/lb of nickel net of  copper credits
  • Plans for Kenbridge include updating PEA, advancing the project through to feasibility and exploring the open mineralization at depth

Recent News

  • Company has completed a Spectral Analysis Survey
  • Survey covered the patented and single-cell mining claims that make up the historic land position which contains the Kenbridge Deposit and the surrounding area, identifying several new exploration targets not only for nickel, copper, cobalt, but also for potential gold occurrences
  • Analysis Survey shows the distribution and intensity of up to 304 minerals, with the first pass showing up to 16 minerals
  • Each mineral can be classified into an exploration relevance for base metals, precious metals and industrial metals

Tartisan CEO Mark Appleby said, “the survey picked out the Kenbridge Deposit, and has shown the possible extension to the Kenbridge Deposit and three additional trends that relate directly to underlying geology and structure implicit in the Kenbridge Deposit. Of significant interest, the survey found two gold trends as well, which include the Violet and Nina historic gold occurrences. One of the occurrences is almost 54 hectares in size and covers almost all of three of our staked claims on the border of the Kenbridge property.”

Industry News

INDUSTRY BULLETIN: Nickel prices jump after Vale trims output target

INDUSTRY BULLETIN: Nickel prices get a boost from pandemic-driven ore supply tightness

INDUSTRY BULLETIN: Have the next crop of battery metals producers been oversold?

INDUSTRY BULLETIN: The thematic case for nickel

Click Here to View Kenbridge 43-101 Technical Report

FULL DISCLOSURE: Tartisan Nickel Corp. is an advertising client of AGORA Internet Relations Corp.

CBD In Medicine: Relief and Regulation SPONSOR: Mota Ventures $MOTA.ca $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 11:40 AM on Tuesday, April 21st, 2020
  • Neuropharmacologist and Functional Medicine practitioner Dr Elisabeth Philipps tells MCN about the therapeutic benefits of CBD and talks about CBD regulation.

MCN speaks to Dr Philipps about the science behind the health benefits of CBD and the need for standardised regulation of CBD food supplements.

Dr Elisabeth Philipps is a neuropharmacologist and practitioner in Functional Medicine with over 18 years’ experience. She operates a thriving health consultancy in the UK specialising in CBD, brain and gut health; where she provides expert opinion for private clients, corporate business programmes, the national media, specialist healthcare publications and health companies.

How did you first become aware of the endocannabinoid system and the therapeutic benefits of cannabis?

I’m a neuropharmacologist by training, so I’ve been aware of the medicinal therapeutic benefits of cannabis for a number of years. The endocannabinoid system was only discovered in the 1990s so it’s actually a relatively recent system that we’ve known about in the body, but it’s only been in the last two to three years that my focus has become much more intense on the endocannabinoid system, medicinal cannabis and CBD oil supplements; because of the rise in profile of those products.

What are the potential dietary benefits of consuming CBD or hemp?

The two products are quite different: hemp is extract of the whole plant, so the dietary benefits of hemp normally come from the hemp seed – you could have the seeds ground or sprinkled on top of your food, for example; maybe hemp seed oil which makes a good salad dressing. Hemp oil extracts are rich in very beneficial omega-3 and omega-6 essential fatty acids; you also find things like protein and fibre as well as minerals and vitamins: magnesium and phosphorus, for example, are found within the hemp seeds themselves.

CBD is an even more refined extract from the hemp plant flowers rather than the seeds, so there’s not so much [in the way of] dietary benefit; but it contains the compounds such as the phytocannabinoids, and other compounds such as flavonoids and terpenes, which can confer health benefits; so you get the dietary benefits from hemp seeds and hemp seed oil and you get other health benefits from consuming CBD.

What kind of conditions and ailments do you find that people are using CBD for?

[There are] three primary areas that people find CBD works for them: the sleep area, to help improve the quality of sleep; people report being able to [get to] sleep more easily, stay asleep and feel more refreshed when they wake up. [The second area is] pain, which comes in many different forms – it can be nerve pain or neurogenic pain or inflammatory pain, so conditions such as arthritis, for example, or more acute conditions such as sporting injuries or general inflammatory injuries. People report taking CBD oil as helping to reduce the response to pain. What’s been very interesting in the study of CBD and phytocannabinoids in pain pathways is that not only is it blocking the pain pathways themselves in the spinal cord and brain, but also CBD acts within the parts of the brain that helps change our perception of pain. That’s really key, because it’s how we respond to the pain signals in our bodies that gives us the intensity of the experience; so CBD is an important component of a programme to help manage different types of pain.

The third area that I find CBD can really help is in mood, in particular [for patients who are] feeling anxious or stressed. CBD has this ability, through various pathways in the brain, to help balance the systems that help us feel better, to improve wellbeing, to improve our mood. CBD works at the neurotransmitter level, transmitting chemicals in the brain that send signals to help provide a balance. There are a number of studies coming in: they’re relatively small scale, but they’re looking at CBD oil for anxiety and for sleep and they have showed improvement in those areas; but the science is beginning to play catch-up now as well.

What is the science behind the effects of CBD on different symptoms?

CBD interacts with our own endocannabinoid system and I think that’s really key, because when you take a medicine it’s a very blunt tool: it either turns something on or turns something off; it blocks a response or it produces a response. CBD is lot more subtle than that within the body, because it works within the endocannabinoid system and that system is spread throughout our body – the endocannabinoid system is in the gut, the brain, in the immune cells, in the lungs, in the skin – so that’s why CBD can have such a diverse number of effects.

We produce our own cannabinoids within the body to stimulate and produce effects; and CBD helps balance the body’s production and the body’s ability to activate the endocannabinoid system through its own naturally produced mediators. There’s a lot of science showing how CBD acts within the endocannabinoid system and produces its responses.

What advice do you have for consumers when choosing a brand or product to ensure it is good quality and does not contain any unlisted ingredients?

This can be a very confusing area, because there are so many products that have hit the market. First of all, a CBD food supplement is legal in the UK if it contains less than 0.2% THC or tetrahydrocannabinol. That is the cannabinoid which causes the commonly associated high or buzz that you get from marijuana; it’s only present in hemp in very low levels anyway and it’s been stripped out of CBD oil. You need to ensure that you’re taking a legal product that contains less than 0.2% THC; and you can do that by asking the company for a certificate of analysis.

Every batch of CBD oil that a reputable company receives will have had a third-party laboratory testing [conducted] on that particular batch of oil, which will have a batch number so it can all be traced. That will show the breakdown of the different cannabinoids and the different constituents of that particular oil so you’ll be able to see not only that it contains the legal limit or less of THC, but the amount of CBD that it says on the label as well – that’s where the product can vary drastically, so you need to have a look at that certificate of analysis to show that it contains the CBD that you want. You will find some companies selling 0% THC products, which are very useful especially if you are drug tested for work or if you’re a professional athlete. The Banned Substances Control Group (BSCG) can test for THC and other banned substances and can provide a certificate to show that you don’t have any of those substances within your product. Reputable companies should have their certificates of analysis on their websites; or have a chat with them and they should provide that information for you.

How do you anticipate the market will evolve in over the next few years?

This is a very interesting time for CBD and medical cannabis: there’s obviously a lot going on and there’s a lot in the news. I think there needs to be more CBD regulation within the industry, because there’s a wide range of products on the market that differ in terms of their CBD content and what they purport to have in them; so there needs to be more CBD regulation, there’s no doubt about that. Equally [there is a question of] how that CBD regulation is brought in: the industry is playing catch-up in a way because the popularity of the product has grown exponentially in the last few years.

What we need to see is regulation, working with food standards agencies and [other regulators] at a government level. I think that will evolve over the next few months and years; and it’s going to be [because of] FourFive and other reputable companies that are working with the regulators, to help the industry in a way that protects it and still provides consumers with quality products.

Working on the assumption that further CBD regulation is likely to be introduced, do you expect this to impact patients using these products?

There is no doubt that the CBD regulation will change; and that it needs to protect the industry in terms of protection of products and protect consumers as well. I think it’s a case of companies and experts working with both agencies and the regulators: the impact on patients is our primary concern; and we are working towards avoiding any impact so there is seamless availability of quality products on the market. That is a goal that everyone is working to at the moment: every country is different and we’re just going to have to keep working together to make sure that high quality products [are going] to be readily available.

Do you anticipate Brexit having an impact, either positive or negative, on CBD regulation and medicinal cannabis regulation?

Brexit will potentially free up time and space for this topic to be higher up agendas. I believe that Brexit has possibly moved discussions of CBD and medical cannabis off the table or further down the list [of priorities]. I do think we’ll see more discussions happening in the next few weeks and months as Brexit resolves. At the moment we’re still working under European guidelines, in terms of the food supplement side at least, but it will be interesting to see how that pans out as we leave Europe; and as with many different areas of Brexit it’s still a bit of an unknown as to how EFTA’s [the European Free Trade Association] regulations and rules will affect the Food Standards Agency on the UK side. There will definitely be more discussion around this, certainly in the groups that I’m involved with; and we know that there are greater discussions to be had in the next few months.

Dr Elisabeth Philipps
Nutritional Therapist
www.hartwellnutrition.co.uk

SOURCE: https://www.healtheuropa.eu/cbd-in-medicine-relief-and-regulation/99418/

Datametrex $DM.ca Provides Update On Health Canada Submission & Welcomes Advisors

Posted by AGORACOM-JC at 7:12 AM on Tuesday, April 21st, 2020
  • Provides additional specifics on the previously announced news release regarding acquiring the rights to import COVID-19 test kits from South Korea
  • An application for approval was made to Health Canada under the Fast-Track program on April 9th, 2020
  • As part of the submission, the Company has submitted a Medical Devices Interim Order Request Form under Interim Order
  • Interim Order (IO) will allow Health Canada to issue expedited review and approval for the sale of these test kits in Canada

TORONTO, April 21, 2020 — Datametrex AI Limited (the “Company” or “Datametrex”) (TSXV: DM, FSE: D4G, OTC: DTMXF ) wishes to provide additional specifics on the previously announced news release regarding acquiring the rights to import COVID-19 test kits from South Korea. An application for approval was made to Health Canada under the Fast-Track program on April 9th, 2020.

As part of the submission, the Company has submitted a Medical Devices Interim Order Request Form under Interim Order Respecting the Importation and Sale of Medical Devices for Use in Relation to COVID-19 pursuant to subsection 30.1(1) of the Food and Drugs Act signed by the Minister of Health on March 18, 2020. This Interim Order (IO) will allow Health Canada to issue expedited review and approval for the sale of these test kits in Canada.

The Company has represented to Health Canada that it will be able to provide a minimum first order of 200,000 units, followed by an additional 100,000 units on a weekly basis. Any purchase of the test kits by the Canadian government is conditional on prior receipt of Health Canada approval. Datametrex is currently working with Dr. Lisa Palleson-Stallan and Dr. Joseph Curtis to assist with obtaining Health Canada approval, and each has agreed to join the Company’s advisory board.

Dr. Joseph Curtis is the Chief Scientific Officer and founder of BioQuant Laboratories (BQL) an independent testing laboratory providing analytical testing services to firms across the U.S. and Canada developing natural product medicines for human and animal health. Dr. Curtis has twenty-five years of experience across and has held various executive positions within public and private sector firms. Working across the public health emergency medical countermeasures continuum, he supported the USA’s blood and tissue preparedness and response programs managed by the American Red Cross. In this capacity, he served as the Director, Biomedical Headquarters Facility Quality Assurance coordinating performance excellence programs across a nation-wide network of manufacturing and testing facilities delivering $2 billion of cellular therapies and transfusion medicine products to over 3,000 hospitals across the US.

Dr. Lisa Palleson-Stallan obtained her Ph.D in International Business with Honours in the U.K. She ran a European Union funded project on technology and Innovation and completed post doctoral work at the World Health Organization (WHO) publishing on Tobacco Cessation. She created her first retail company, Lotuswear, which grew into a 100 employee + company and had the role as presidentand CEO. She became an early adopter in several industries and has continued building value from the ground up. She has built a successful consultancy company that targets the Asian marketplace within the Health space. Dr Palleson-Stallan has been given role and title of Global Health Advisor to assist the Chinese Government with unconditional support and authority to conduct negotiations regarding how to best to combat the spread of Covid-19.

“We are thrilled to be in a position to bring high quality test kits to Canada to help flatten the curve and save lives. We are doing everything we can to provide Health Canada with the required information to move forward. We are looking forward to solving these problems alongside Dr. Palleson-Stallan and Dr. Curtis.”, says Marshall Gunter, CEO of the Company.

Datametrex anticipates that it will have little or no upfront costs associated with importing these test kits. Assuming Health Canada approves the test kits and they are subsequently purchased by the Canadian government, manufacturer will ship the test kits directly to the Canadian government or hospitals, and Datametrex will not be involved in the shipping, warehousing or distribution process.

About Datametrex AI Limited

Datametrex AI Limited is a technology-focused company with exposure to Artificial Intelligence and Machine Learning through its wholly-owned subsidiary, Nexalogy (www.nexalogy.com).
Additional information on Datametrex is available at www.datametrex.com

For further information, please contact:

Marshall Gunter – CEO
Phone: (514) 295-2300
Email: [email protected]

Jeff Stevens – Co-Founder
Phone: (647) 400-8494
Email: [email protected]

Neither the TSX Venture Exchange nor it’s Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations, and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

NORTHBUD $NBUD.ca – Virtual 4/20: How the #Cannabis Industry Is Adapting Its Signature Holiday for Quarantine $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 9:30 PM on Monday, April 20th, 2020

SPONSOR: NORTHBUD (NBUD:CSE) Sustainable low cost, high quality cannabinoid production and procurement focusing on both bio-pharmaceutical development and Cannabinoid Infused Products. The company recently received Canadian Cultivation Licence for its Quebec Facility. Learn More.

Virtual 4/20: How the Cannabis Industry Is Adapting Its Signature Holiday for Quarantine

Dispensaries get creative, and celebrities join in, as gatherings give way to livestreams

  • Despite all the gloom facing society as 4/20 approaches, it’s predicted to be a massive sales day, contributing to what BDS Analytics thinks will be a 30% jump in retail cannabis sales this year to $17 billion.

  By T.L. Stanley Harvest House of Cannabis  

Many cannabis fans are as devoted to their unofficial holiday, April 20, as some people are to Christmas, Halloween or the Fourth of July. In recent years, as cannabis has grown in mainstream acceptance and legality, 4/20 has been marked with parties and concerts, stadium-sized festivals and pot versions of pub crawls.

But not this year, as the coronavirus response has blocked public gatherings, gutted the experiential industry, canceled nearly every major 4/20 event and substantially altered marketers’ approaches  to the day.

The celebrations will go on, though, as organizers pivot from real-world to virtual gatherings, lining up talent like Wiz Khalifa, Billy Ray Cyrus, Berner and Kid Astronaut for marathon live streams that revelers can watch from the safety of their couches.

Delivery services are prepped for heavy volume in the wake of a record-setting mid-March sales surge, and brands in the space are giving consumers quarantine-friendly ideas to replace their usual in-person meetups and smokeouts. “This is a chance for the cannabis community to model to the rest of the world how holidays should be handled during periods of social crisis.” —Steve DeAngelo, co-founder, Harborside dispensary

Dispensaries in states where they’re considered “essential businesses”—and therefore allowed to stay open, while following strict safety protocols and social distancing rules—are leaning into their curbside pickup and contactless delivery options. They’ll be trying to discourage exactly the kinds of crowds at their venues that they’ve actively fostered in the past.

Mainstream, non-cannabis brands that have latched onto the holiday with psychedelic stoner-cliched ads and memes may sit it out all together, similar to this year’s approach to April Fools’ Day, so as not to appear flip or insensitive (or simply wasteful with their resources) during the current pandemic and economic downturn.

All things considered, 4/20 is expected to shed some of the raucous overkill and “amateur night” feel of the recent past in favor of a more thoughtful, subdued vibe.  

“You don’t generally associate 4/20 with restraint,” says Steve DeAngelo, a longtime cannabis activist and co-founder of the Harborside dispensary chain in the Bay Area. “But this is a chance for the cannabis community to model to the rest of the world how holidays should be handled during periods of social crisis.”

Taking no chances, the mayor of San Francisco has publicly warned cannabis devotees not to travel to or gather in the famously open-minded destination, known for its 4/20 meet-ups in places like Golden Gate Park. “We will cite people. We will arrest people if necessary,” London Breed says in an Instagram video. And the Washington State Liquor and Cannabis Board sent out a list of do’s and don’ts to licensed businesses, telling them not to schedule events, hire food trucks or live bands or try in any way to attract large crowds.

Another green rush

Despite all the gloom facing society as 4/20 approaches, it’s predicted to be a massive sales day, contributing to what BDS Analytics thinks will be a 30% jump in retail cannabis sales this year to $17 billion. 

One of the previous high water marks for the industry was April 20, 2019, when recreational cannabis sales increased more than 100%, versus the prior week, in states like California, Colorado, Nevada and Washington, according to cannabis data firm Headset.

“Since 4/20 is on a Monday this year, the sales uptick could start over the weekend or maybe even mid-week,” says Liz Connors, Headset’s director of analytics.

Weedmaps, a national cannabis delivery platform, is girding for a second green rush, following the March spike in sales as stay-at-home mandates were announced. “Conservative estimates could very well put us around eight times the order volume over our baseline, and four to five times what we typically see on this holiday annually,” according to CMO Juanjo Feijoo.

Source: https://www.adweek.com/creativity/virtual-4-20-how-the-cannabis-industry-is-adapting-its-signature-holiday-for-quarantine/

Nickel prices jump after Vale trims output target – SPONSOR Tartisan #Nickel $TN.ca – $ROX.ca $FF.ca $EDG.ca $AGL.ca $ANZ.ca

Posted by AGORACOM-JC at 9:15 PM on Monday, April 20th, 2020

SPONSOR: Tartisan Nickel (TN:CSE)  Kenbridge Property has a measured and indicated resource of 7.14 million tonnes at 0.62% nickel, 0.33% copper. Tartisan also has interests in Peru, including a 20 percent equity stake in Eloro Resources and 2 percent NSR in their La Victoria property. Click her for more information

Tc logo in black

Nickel prices jump after Vale trims output target

  • Vale cuts 2020 output for nickel, copper
  • “Vale’s cut to production has supported the market but mines closing production is not too new as we knew some mines would shut,” said Commerzbank analyst Daniel Briesemann.

By Zandi Shabalala

LONDON, April 20 (Reuters) – Nickel prices jumped to their highest in more than a month on Monday after mining company Vale slashed its annual output target for the stainless steel ingredient due to the impact of the coronavirus pandemic.

Benchmark nickel on the London Metal Exchange (LME) was 4% higher at $12,520 per tonne at 1600 GMT, after earlier jumping to its highest since March 13 at $12,535.

“Vale’s cut to production has supported the market but mines closing production is not too new as we knew some mines would shut,” said Commerzbank analyst Daniel Briesemann.

“The negative impact of the virus is more severe for the demand side and the market could be well oversupplied this year.”

Vale, one of the world’s top producers of nickel, cut its 2020 production forecast for the metal to 180,000-195,000 tonnes from 200,000-210,000, excluding its unit in New Caledonia, because of the impact of the novel coronavirus outbreak.

Japan’s Sumitomo Corporation has also shut down output at a nickel mine in Madagascar while major nickel producer the Philippines closed some of its mines to curb transmission of the virus.

CHINESE DEMAND: Demand for nickel picked up slightly in March as China reopened its economy. Stainless steel futures surged as much as 4.4% on Monday.

2020 BALANCE: Despite the mounting supply cuts, a Reuters poll showed that the nickel market is expected to be in surplus of 89,000 tonnes this year.

CHINA ECONOMY: China, the world’s top metals consumer, cut its interest rate for a second time after its economy contracted for the first time in decades. The move – which was widely expected – is aimed at cushioning the world’s second largest economy against the impact of the coronavirus.

COPPER SMELTING: Global copper smelting slid in March, driven by shutdowns in China but started to recover at the end of the month, according to an index based on satellite surveillance of copper plants.

ALUMINIUM INVENTORIES: Aluminium stocks in LME-registered warehouses soared 46,275 tonnes, helping to lift inventories available to the market to 1.18 million tonnes which is the highest since Dec. 20. MALSTX-TOTAL

SPREAD: The discount of LME cash aluminium to the three-month contract CMCU0-3 was at $37.75 a tonne, reflecting expectations for oversupply.

Read More: https://www.reuters.com/article/global-metals/metals-nickel-prices-jump-after-vale-trims-output-target-idUSL4N2C82C3

80% of Americans believe they read #coronavirus “fake news” in the early stages of the epidemic – SPONSOR: Datametrex AI Limited $DM.ca

Posted by AGORACOM-JC at 5:34 PM on Monday, April 20th, 2020

SPONSOR: Datametrex AI Limited (TSX-V: DM) A revenue generating small cap A.I. company that NATO and Canadian Defence are using to fight fake news & social media threats. The company is working with US Government agencies on Covid19 and Coronavirus fake news and disinformation Click here for more info.

80% of Americans believe they read coronavirus “fake news” in the early stages of the epidemic

  • A Pew survey of 8,914 US adults found that 4 in 5 Americans believe they were misled by the media about the coronavirus situation
  • About half of the participants gave examples of this misinformation, and at least a part of it wasn’t actually fake news

by Mihai Andrei

We’ve been covering the COVID-19 pandemic since January, when it was still a “mysterious virus in Wuhan”. Like everyone else, we didn’t know what to make of it at first — and we were shocked to see how quickly and dramatically the situation developed.

We did our best to cover the available information accurately, but we noticed something weird happening in the comment section and the emails we were getting. A lot of people were upset with our coverage and felt like we weren’t communicating the threat properly — about half of the complaints were saying we were exaggerating the risks. The other half claimed we weren’t explaining the risks enough. Source: Pew Research Center.

A similar feeling seems to be reported in much of the American population. The largest group of responses in the Pew survey (41% of all who provided claims) felt they were misled about the level of risk. The sentiment was divided into two roughly equal sides: 22% felt the information falsely elevated the risk, while 15% felt it downplayed the risk. In particular, people in the latter group cited not only the media but also the administration and the president, who promised an early end to the problem and repeatedly underplayed the risks posed by the coronavirus.

It’s safe to say that President Trump’s intervention has been a major contributor to misinformation, as he repeatedly came out saying that the coronavirus is less dangerous than the flu. But this statement was also found in several media outlets. Just as the administration fumbled its response on multiple levels, so, too, did the media by taking too long in communicating a clear message about the coronavirus situation.

It was only on March 15 when the CDC told the country to stop gathering in groups, and at the time, the virus was already spreading in the US. The government also urged people not to buy any type of face masks, but then changed its recommendation, causing even more confusion.

Americans’ opinions are also mixed about how much misinformation they have seen. According to the Pew survey, 12% believe they’ve seen “a lot”, and 20% believe they’ve seen “none at all”, with the rest stating that they’ve seen “some” or “not much” misinformation.

Source: https://www.zmescience.com/science/80-of-americans-believe-they-read-coronavirus-fake-news-in-the-early-stages-of-the-epidemic/

MOTA Ventures $MOTA.ca Generates $4.29 Million in Revenue During March 2020 $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 9:23 AM on Monday, April 20th, 2020
Mota large
  • Generated CAN$4,290,000 with related expenses of $4,240,000
  • The Immune Support product line experienced further positive growth contributing to First Class acquiring 20,959 new customers during the month of March

VANCOUVER, BC / ACCESSWIRE / April 18, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTCPINK:PEMTF) (the “Company“) is excited to announce that for the month of March 2020, its First Class CBD brand achieved sales of Cdn$4,290,000, with related expenses of Cdn$4,240,000. Customer acquisition expenses for March 2020 include one-time costs of approximately Cdn$1,160,000 associated with the introduction of the new line of Immune Support and CBD products. The Immune Support product line experienced further positive growth contributing to First Class acquiring 20,959 new customers during the month of March. The all-natural Immunity Blend is made from 100% pure essential oils, including cinnamon leaf, lemon, clove bud, lime, eucalyptus globulus, rosemary, peppermint, spearmint and oregano. The Company also launched an Immune CBD oil, along with an Elderberry Gummy product. The new Immune CBD product contains CBD, B3, B12, Vitamin C and Zinc. Sales for March 2020 compare to sales of Cdn$1,280,000 during the same period last year, representing an increase of 235%.

The Company also introduced a new brand, Nature’s Exclusive CBD, in the first week of April 2020. The Nature’s Exclusive CBD brand will offer a range of products, which include the new Immune CBD oil, Elderberry gummies, CBD oil drops, CBD gummies, CBD pain relief cream, CBD skin serum and CBD coffee.

First Class offers a CBD hemp-oil formulation intended to provide users with therapeutic benefits that hemp may offer. The hemp oil used in the products is derived from hemp grown and cultivated in the United States. The extraction process is designed to maintain all the beneficial qualities that hemp may offer. First Class offers a range of products, which include CBD oil drops, CBD gummies, CBD pain relief cream, CBD skin serum and CBD coffee. First Class plans to continue its significant growth in their U.S. operations over the balance of 2020, as well as an expansion into the European market.

“I am extremely pleased with the performance of our business during March 2020, a month where the world and the economy faced immeasurable challenges. Our ability to efficiently innovate and launch new products, is a perfect example of our primary competitive advantage, and what allows us to be a leader in the ecommerce space. We expect our investment in accelerated customer acquisition from February to March, including a one-time cost of Cdn$1,160,000, will continue to produce significant revenue growth, and are hopeful it will lead to increased profitability in the upcoming months,” stated Ryan Hoggan, CEO of the Company.

The Company cautions that figures for revenue, expenses and margin generated from the sale of First Class CBD products have not been audited, and are based on calculations prepared by management. Actual results may differ from those reported in this release once these figures have been audited. These figures were translated from US dollars into Canadian dollars using the Bank of Canada monthly average exchange rate of US$1.00:Cdn$1.3953 for March 2020 and US$1.00:Cdn$1.3368 for March 2019.

About Mota Ventures Corp.

Mota is an established ecommerce, direct to consumer provider of a wide range of CBD products in the United States and Europe. In the United States, the Company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its First Class CBD and Nature’s Exclusive brands. Within Europe, its Sativida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS

MOTA VENTURES CORP.

Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

AGORACOM Welcomes Else Nutrition $BABY.ca – The Award Winning, Plant-Based Nutrition Company For Small Cap Investors; $10,000,000 Cash Balance For US product Launch In Q2 2020, Int’l Agreements Q3

Posted by AGORACOM-JC at 8:30 AM on Monday, April 20th, 2020

Highlights

  • $CAD 10 million cash and runway for well over a year;
  • Backed By A Billion Dollar Global Nutrition Company;
  • MOU For International Distribution Of Products
  • US Product Launch Planned For Q2-2020;
  • “Best Health” Award At Global Food Innovation Summit In Milan;
  • Awarded Patents In 22 Countries, 44 Countries Pending;
  • Executives & Advisors From Globally Renowned Companies & Institutions

Why Else Nutrition?

  • Gives Small Cap Investors An Opportunity To Participate In Global Paradigm Shift Towards Plant-Based, Clean Label Foods For Toddlers & Children.
  • Entering Commercialization Stage After 7 Years R&D
  • Launching 1st Commercial Product Into US Market Q2
  • 100% Plant-Based, Organic Toddler Nutrition Product 
  • Market Research Survey Finds Over 60% Positive Purchase Intent For Else Product
  • Fills A Market Gap In Plant-Based Toddler Nutrition (12-36 months)
  • Subsidiary Of Billion Dollar Hong Kong Listed Conglomerate (H&H) Owns Approx 11.15% Of BABY
  • H&H Shares Have Voluntary 12-Month Hold
  • H&H Right To Maintain 11.15% Ownership Through Future Financings
  • Patented World’s First 100% Plant Based, Non-Dairy, Non-Soy Baby Formula

Here’s What The Experts Say

“Finally a high quality, nutritionally-dense, tasty, plant-based alternative that is low in sugar.  Else is filling a much needed gap, and providing an alternative for those looking to avoid dairy or soy, and a viable option for intolerances and other diet considerations.”

Nicole Silber, RD, CSP, CLC

Dairy-free, soy-free, plant-based nutrition for babies and toddlers

Else Nutrition (formerly INDI) won the “2017 Best Health and Diet Solutions” award at the Global Food Innovation Summit in Milan.

The Product

Else Plant-Based Toddler Nutrition

Dairy-free | Soy-free | Corn Syrup-free | Gluten-free

baby-100

Made with real, whole foods, it meets the highest standard for nutrition

  • Endorsed by leading pediatricians and nutritionists 
  • Ingredients, vitamins & minerals to support your child’s growth and development
  • 92% whole plant ingredients (almonds, tapioca, buckwheat) 
  • Organic & non-GMO
  • Made by the cleanest process possible
  • Globally patented 
nutrition
BABY-screen1

LEARN MORE!

Hub On AGORACOM / Corporate Profile

Else Nutrition $BABY.ca Announces Expansion of Intellectual Property Portfolio to India and Canada

Posted by AGORACOM-JC at 8:24 AM on Monday, April 20th, 2020
  • Announced that the Company has expanded its intellectual property (IP) portfolio to India and Canada
  • Received a formal grant from the Indian Patent office for its patent application 640/CHENP/2015, and a notice of allowance from the Canadian Intellectual Property Office for its patent application 2898980, for its proprietary, clean, plant-based formulation for infant and toddler populations

VANCOUVER, BRITISH COLUMBIA / April 20, 2020 / ELSE NUTRITION HOLDINGS INC. (TSXV:BABY)(OTCQB:BABYF) (“Else” or the “Company“), a developer of novel plant-based infant and toddler nutrition, is pleased to announce that the Company has expanded its intellectual property (IP) portfolio to India and Canada.

The Company has received a formal grant from the Indian Patent office for its patent application 640/CHENP/2015, and a notice of allowance from the Canadian Intellectual Property Office for its patent application 2898980, for its proprietary, clean, plant-based formulation for infant and toddler populations.

“These are highly encouraging developments in key growth markets as we aim to extend our global reach and impact,” stated Ms. Hamutal Yitzhak, Else Nutrition CEO & Co-Founder. She added, “We continue to hear from parents across all geographies that our clean, plant-based infant and toddler formulations can provide a viable alternative for parents seeking an alternative to formulas which contain cow’s milk protein or soy protein.”

Additionally, since March 11, 2020, the Company has engaged AGORACOM for investor awareness, marketing and branding services (the “Advertising Services“). As consideration for the Advertising Services, Else will issue an aggregate of $60,000 plus applicable taxes in the form of common shares of Else (the “Shares“). The Shares are payable in five equal installments during a period from April 2020 until March 2021 for a total term of one-year, as further provided in the online marketing agreement between the Company and AGORACOM. The number of Shares to be issued each time an installment is due will be determined by using the closing price of the Shares of Else on the last trading day following each period for which the Advertising Services were provided. In accordance with Policy 4.3 – Shares for Debt, each Share issuance installment is subject to approval from the TSX Venture Exchange. The number and amount of each issuance will be disclosed by way of a press release when such Shares are issued.

About Else Nutrition Holdings Inc.

Else Nutrition GH Ltd. is an Israel-based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the “2017 Best Health and Diet Solutions” award at the Global Food Innovation Summit in Milan. The holding company, Else Nutrition Holdings Inc, is a publicly-traded company, listed as TSX Venture Exchange under the trading symbol BABY and is quoted on the US OTC Markets QB board under the trading symbol BABYF. Else’s Executive and Advisory Board includes leaders hailing from Abbott Nutrition, Mead Johnson, Boston Children’s Hospital, ESPHGAN (European Society for Pediatric Gastroenterology, Hepatology and Nutrition). Plum Organics, Tel Aviv University’s Sackler Faculty of Medicine, and Gastroenterology & Nutrition Institute of RAMBAM Medical Center.

For more information, contact:

Ms. Hamutal Yitzhak, CEO, Co-Founder & Director
Else Nutrition Holdings Inc.
E: [email protected]

Mr. Sokhie Puar, Director of Else Nutrition Holdings Inc.
Telephone: 604-603-7787
Email: [email protected]

TSX Venture Exchange

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Statements

This press release contains statements that, to the extent they are not recitations of historical fact, constitute “forward-looking statements” within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as “will”, “to be”, “intend” or similar expressions. Forward-looking statements in this press release include, but are not limited to, statements with respect to the Company’s expected go-to-market strategy (including marketing, proposed markets, sales, customer growth and market position) and the share issuances made to AGORACOM.

Such forward-looking statements reflect current estimates, beliefs and assumptions, which are based on management’s perception of historical trends, current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct.

Forward-looking statements made in this press release assume, among others, the successful completion of Else’s proposed scale-up for its products, and such statements are intended to apply only to the infant formula market for ages 12 months and above, and having all necessary regulatory approval as required by each target market.

Numerous risks and uncertainties could cause the Company’s actual results to differ materially from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements, including, but not limited to: consumer demand for the Company’s products, whether the Company’s current and future products achieve commercialization, uncertainty regarding material changes in laws and regulations and the Company’s ability to expand into global markets.

In addition, the Company is subject to risks and uncertainties caused by the COVID-19 pandemic which has resulted in governments worldwide enacting emergency measures to combat the spread of the virus including travel bans, self-imposed quarantine periods and social distancing. The outbreak of COVID-19 can impact our operations in a number of ways including quarantined employees, travel restrictions, temporary closure of our office, as well as interruptions to our manufacturing and supply chains.

The foregoing list of factors is not exhaustive, and other risks and uncertainties not presently known, or believed to be material, to management and other factors that could affect the operations or financial results of the Company are set out in the Company’s Filing Statement dated May 14, 2019 under the heading “Risk Factors” and may be accessed through the SEDAR website (www.sedar.com).

Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management’s expectations only as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

SOURCE: ELSE Nutrition Holdings

Hollister Biosciences Inc.$HOLL.ca Division Hollister #Cannabis Co Becomes Official Brand Partner for Chronic Relief 4/20 Fundraiser in Support of Feeding America $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 7:20 AM on Monday, April 20th, 2020
  • Through its Hollister Cannabis Co division, has become an official brand partner of Farechild Events’ Chronic Relief 4/20 fundraiser.
  • Virtual event has been established to help the Feeding America network of food banks as they support communities and families impacted by the COVID-19 pandemic.

Hollister Biosciences Inc., the creator of California’s #1 hash-infused pre-roll HashBone, joins a global group of cannabis’ biggest stars for an unprecedented live web broadcast on one of the world’s “highest” holidays to feed hungry families during the global coronavirus pandemic.  

VANCOUVER, April 20, 2020  – Hollister Biosciences Inc. (CSE: HOLL, OTC: HSTRF, FRANKFURT: HOB) (the “Company” or “Hollister“) – through its Hollister Cannabis Co division, has become an official brand partner of Farechild Events’ Chronic Relief 4/20 fundraiser. 

An extraordinary line-up of game-changing cannabis personalities, activists, actors, musicians, athletes, journalists and brands have banded together for Chronic Relief – a ground-breaking free telethon live-web broadcast, with 100% of all funds raised via donation given to Feeding America COVID-19 Response Fund (501c3). This virtual event has been established to help the Feeding America network of food banks as they support communities and families impacted by the COVID-19 pandemic. Households facing hunger may be more susceptible to the virus, further contributing to the demands placed on food banks. Your donation will enable food banks to serve the most vulnerable members of the community and our neighbors in need, during this difficult time.

Uniting the global cannabis community in celebration of 4/20 by bringing entertainment, words of encouragement, and the giving spirit to those in need; famed cannabis event producers Dave Tran and James Zachodni of Farechild Events, Seattle-based Atomic Studios, lifestyle brand/canna-marketing company Dab Star and award-winning branding agency Wick & Mortar, along with others, come together to support those facing hunger as a result of COVID-19. 

The cannabis community has embraced Chronic Relief en masse by supporting the upcoming event through a wide array of platforms in an effort to ignite passion in the American people showing that cannabis cares and is here to feed your body and mind. Brands and companies who have offered to support include: Sensi Magazine, Marijuana Venture Magazine, Cannabis Club TV, Cannabis Talk 101, PufCreativ, Enlighten, Cannabis & Tech Today, Pot Brothers At Law, Cannacon, Cannabis Now Magazine, Happy Munkey, Leaf Magazine, Haze Radio, Revel, Hempfest, Dab Tabs, Futurola, 420 Games, NECann, Respect My Region, Cannabis Alliance, Daily Leaf, Sound Cultivation, LA Cannabis News, Dip Devices, My Cannabis Accountant, Scynce LED, and Chapter 2.

“We’re at the threshold of an extreme moment of need in our human existence,” said Dave Tran, organizer of the event and one of the executive producers of the Chronic Relief broadcast. “There’s countless families who are surviving this crisis hungry, scared and unsupported. We have the network, we have the passion, we have the technology to raise awareness. Most importantly Feed America needs the funding to do their incredible work during this crisis. The support we’ve received from the cannabis media and industry community is remarkable. James and I’s phones are blowing up with everyone asking, ‘What can I do and how can I help?’ We hope our viewers all over the country will do the same on 4/20.” 

Farechild Events further shared about this event: “In our current state of uncertainty, we know it’s essential to unite as a community to offer strength and optimism during this international crisis. The cannabis industry was built on the giving spirit and if there has ever been a time to harness the strength of the cannabis community, it’s now. Let’s come together to support those facing hunger as a result of the COVID-19. 

We have the opportunity to make this 4/20 the most iconic celebration in our community’s history. There is no better time than the present for the cannabis space to make a lasting impact where it matters most. As all major 4/20 celebrations have been cancelled, we have the opportunity to leverage our partnerships and vast network of supporters to capture a large audience of virtual cannabis enthusiasts in support of a virtuous cause. Cannabis consumers and advocates are looking for a way to connect with their peers on 4/20 and Chronic Relief is the answer.  

In the spirit of legendary fundraisers like the Jerry Lewis MDA Labor Day Telethon, Chronic Relief looks to bring many of the same aspects of the time-honored tradition, but in a virtual world where viewers can join a live-stream. The event will act as a platform to raise money for charity with 100% of all funds raised via donation during broadcast will be given to Feeding America (501c3). A donation link will be visible on the live-stream screen. In addition to the opportunity to donate to feedingamerica.org, viewers can expect to see video segments from artists, influencers and celebrities.  Live musical performances and interviews with influencers will stream live from our Seattle-based studio in a true variety-show format. It will be a 4/20 to remember.”

The CEO of Hollister Biosciences Inc, Carl Saling, shared: “We are honored to be part of Chronic Relief 4/20. So many families are struggling right now and we all must step up and do our part to help.  Hollister Cannabis Co has been making and donating hand sanitizer all over the community.  This event is an opportunity to come together and really do some good.”

Chronic Relief 4/20 is taking place on Monday, 4/20/20 from 12-5PM PST. For more information and to RSVP for this remarkable live-stream fundraiser, please visit farechild.com. 

The Team Behind Chronic Relief

Farechild Events is the premier event production platform focusing on the cannabis industry.

www.farechildevents.com 

Feeding America is a not for profit. As the COVID-19 pandemic continues, we are committed to serving communities and individuals facing hunger across America, wherever they are. Every dollar raised from the COVID-19 response fund will be used to get food and funds to local food banks across the US. You can help make sure we can be there for our neighbors in need during this time of uncertainty. www.feedingamerica.org  

Atomic Studios is our broadcast studio partner and is located in Seattle’s South Lake Union. The studio is designed for live stream productions and includes cameras, lighting, graphics, audio, replay, and the best team in the Pacific Northwest to make it happen. www.atomicinfotech.com 

Wick & Mortar is the award-winning cannabis-focused branding and content marketing agency. Their core services include branding, strategy, copywriting, packaging design, packaging production, and website design. Additional services include marketing consulting, photography, videography, and advertising. For over 10 years, Wick & Mortar has brought a plethora of experience, deep-rooted relationships and polished presentation to some of the most recognized projects in the cannabis industry. www.wickandmortar.com 

About Hollister Biosciences Inc. 

Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products. 

Our wholly-owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker”.

Website:  www.hollistercannabisco.com 

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile onwww.sedar.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/hollister-biosciences-inc-division-hollister-cannabis-co-becomes-official-brand-partner-for-chronic-relief-420-fundraiser-in-support-of-feeding-america-301043070.html